01
Double Materiality Matrix & ESG Risk Management
Goal Setting
PharmaEssentia referenced the GRI 3: Material Topics 2021 of the GRI Universal Standards 2021 released by the Global Sustainability Standards Board (GSSB) in 2021 as well as the Double Materiality principle proposed by the European Union to analyze and confirm material topics.
Process for Identifying Material Topics
We adopted the Double Materiality principle, referenced stakeholder feedback, conducted discussions with the Executive Center for Corporate Sustainability and associated executives, and combined related topics before finally confirming eight material topics.
Material Issues and metrics for Enterprise Value Creation
- Material Issues
- Access to Medicine
- Evaluation of Environmental Impacts from Drug Production Processes
- Doctor-Patient Relationships and Local Empowerment
- Business Case
- PharmaEssentia is committed to helping patients access the medicines they need in a reasonable, affordable, accurate, and convenient manner, thereby enhancing the resilience of healthcare systems, building brand trust, and expanding market coverage.
- PharmaEssentia places great importance on assessing the environmental impact of its production processes. Neglecting environmental impacts could result in regulatory penalties, operational disruptions, and reputational damage, thereby increasing the company’s operational risks.
- PharmaEssentia values building strong doctor-patient relationships within local communities. Through health promotion, medical education, and collaboration with primary healthcare providers, the company strengthens local medical resources and health awareness, enhancing community care capacity and healthcare resilience. This not only fosters local trust and fulfills corporate social responsibility, but also helps PharmaEssentia create a positive impact in the MPN medical field, generating business opportunities for its global strategic development and product advancement.
- Business Impact
- Opportunity
- Risk
- Opportunity
- Business strategies
- PharmaEssentia expands access to its medicines for more MPN patients worldwide by promoting participation in global clinical trials, implementing compassionate use programs, obtaining regulatory approvals in various countries, and ensuring fair and reasonable pricing. By maintaining reasonable pricing and ensuring the safety of drug development, the company secures market authorizations across countries, thereby driving revenue growth.
- PharmaEssentia has implemented the ISO 14001 Environmental Management System and ISO 14064-1 Greenhouse Gas Inventory, continuously improving energy efficiency and reducing waste. The company also upgrades equipment and introduces environmental improvements to manage environmental impact risks. Although these initiatives require higher initial investments, they are expected to help reduce production costs in the long run.
- PharmaEssentia implements “Patient Support Programs” in Taiwan, the United States, and Japan, offering BESREMi medication consultation for MPN patients. The company also regularly hosts the MPN Asia International Symposium, facilitating the exchange of medical experiences and the latest knowledge among healthcare institutions, academic organizations, and patient communities.
- Target/Metric
-
- Doctor-Patient Relationships and Patient Support: Over 10,000 beneficiaries.
- Medicine Accessibility: Regulatory approvals obtained in more than 40 countries.
-
- Toxic Chemical Management: Zero penalty cases.
- Waste Management: Zero penalty cases.
- Global Market Healthcare and Community Empowerment: Over 10 health education events held.
- Target Year
- 2025
- 2025
- 2025
- Progress in 2024
-
- 2024 Achievements:
- Over 10,000 patients benefited.
- Obtained regulatory approvals in 40 countries.
-
- 2024 Achievements:
- Toxic Chemical Management: Zero penalty cases.
- Waste Management: Zero penalty cases.
- 2024 Achievements:
Held 25 health education events.
- Executive Compensation
- Pharmaessentia links the performance indicators of the Chairman, CEO, and General Manager to sustainable development. Key performance indicators include innovative new drug development, global pivotal clinical trials, drug license application, fortify global marketing strategy and business operations, and strengthen corporate social responsibility–sustainability: implementation and improvements.
Material Issues for External Stakeholders
- Material Issue for External Stakeholders
- Access to Medicine
- Doctor-Patient Relationships and Local Empowerment
- Cause of the Impact
- Operations Products/services
Supply chain - Operations Products/services
- Business activity coverage
- >50% of business activity
- >50% of business activity
- External stakeholder(s)/impact area(s) evaluated
- Society
Consumers/end-users
External employees (e.g. supply chain, contractors) - Society
Consumers/end-users
- Topic relevance on external stakeholders
- Positive Impact:
PharmaEssentia’s medicine accessibility management accelerates the acquisition of regulatory approvals in various countries, promotes compassionate use programs and clinical trials, helping MPN patients obtain timely access to necessary medications, thereby contributing to their disease treatment and well-being. - Positive Impact:
PharmaEssentia provides patients with medication and access consultations through its Patient Support Programs and collaborates with healthcare institutions and academic organizations to assist patients in obtaining treatment resources and support, creating a positive impact for stakeholders involved in MPN issues.
- Output Metric
- Assisted at least 10,000 patients
- Held 25 health education events